Navigation Links
Defensive measures: Toward a vaccine for Ebola
Date:12/5/2011

as in the case of common vaccines against diseases like influenza or polio. Instead, the idea is to have a sizeable store of the vaccine on hand in the event of a sudden outbreak, either natural or nefarious.

A killer up close

Ebola belongs to a family of viruses known as filoviridae, which take their name from their serpentine, filamentous structure (see Figure 1). Filoviridae fall into two broad categories known as Ebola-like and Marburg-like viruses. In the original Ebola outbreak in Yambuku, situated along the Ebola River, 280 of the 318 identified cases died. Soon thereafter, an additional 284 cases and 151 deaths occurred in nearby Sudan. In Yambuku, the small local hospital was shut down, after 11 of its 17 staff members died.

The likely reservoir for the disease is bats. Primates including monkeys can become infected from eating bats or from fruit the bats may have dropped. Infected animals can then spread the disease to humans through bites, or when the primates are consumed for fooda practice prevalent in some regions of Africa.

The course of the disease is pitiless, sometimes producing hemorrhagic fever, which causes severe bleeding from mucous membranes, including the gastroinestinal tract, eyes, nose, vagina and gingiva. The very high mortality and gruesome symptoms of the disease have riveted public attention and have been the focus of numerous films and books, notably Richard Preston's The Hot Zone.

Arntzen notes that while no human vaccine against Ebola currently exists, a number of strong candidates have emerged. While some have yielded good results in animal models, in terms of protection against the virus, they have practical shortcomings. "All of these existing vaccine candidates are genetically modified live viruses," he says. Vaccines of this sort require very careful conditions of storage and have a tendency to lose potency over a period of months. "If you've got something that you're g
'/>"/>

Contact: Joseph Caspermeyer
Joseph.Caspermeyer@asu.edu
Arizona State University
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. Cells die so defensive organs can live
2. Rapid venom evolution in pit vipers may be defensive
3. Toward more cost-effective production of biofuels from plant lignocellulosic biomass
4. Leicester leads the way towards a sustainable lake in Africa
5. Advance toward a breath test to diagnose multiple sclerosis
6. Progress towards developing plants that accommodate climate change
7. Wildlife Conservation Society study uncovers a predictable sequence toward coral reef collapse
8. Award-winning research points toward Alzheimer’s vaccine
9. Another step toward resisting breast cancer
10. Toward new medications for chronic brain diseases
11. Toward a more efficient use of solar energy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Defensive measures: Toward a vaccine for Ebola  
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has ... Market 2015-2019" report to their offering. ... is a technology used for the identification of individuals. ... a person such as nose, jaw edges, mouth, and ...
(Date:12/11/2014)... blood pressure plays a role in human health has been ... for high blood pressure – was first described as a ... used in measuring blood pressure was invented in 1896. ... its triggers and its effects. In fact, recent findings have ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Attend the International Osteoporosis Foundation,s key regional meeting ... participate in an enriching scientific programme of direct ... faculty of leading experts from around the world. ... includes... Plenary sessions ...
... of more than 100 studies from around the world shows ... solvents is likely associated with a higher risk of developing ... print issue of Neurology , the medical journal of ... association, there was also a link between farming or country ...
... identified a new regulator for plant hormone signaling -- the ... help to improve production of fruits, vegetables and grains. ... 27 in the journal Proceedings of the National Academy ... controls cytokinin signaling by regulating the degradation of type-B response ...
Cached Biology News:KISS ME DEADLY proteins may help improve crop yields 2
(Date:1/22/2015)... Protocol Networks brings independent technology consulting ... brand-neutral, independent consultants, Protocol Networks has recently announced its ... the years, his company has attracted several clients in ... as well as others. With the success of these ...
(Date:1/22/2015)... WI (PRWEB) January 22, 2015 Dr. Greg ... the 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics ... Conference is an annual continuing education conference for health care ... and included the topic of probiotics in health. Dr. Leyer ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Feb. 9, 2011 HIGHLIGHTS:2010 Results (all percentages ... 2010 reported sales were $582 million, a new quarterly high. Q4 ... adjusted basis, respectively.  Full year 2010 sales increased 6% and 5% ... Q4 2010 reported diluted EPS was $0.76. Excluding restructuring costs ...
... YORK, Feb. 9, 2011 Reportlinker.com announces that ... its catalogue: Strategic Analysis of ... http://www.reportlinker.com/p0376721/Strategic-Analysis-of-European-Human-Machine-Interface-HMI-Market.html This research ... Europe primarily over the two broad categories of ...
... Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR ) ... release after the market closes on February 23, 2011. Due ... be hosting a conference call to discuss its fourth quarter ... Inspiration. Dedication. Innovation. ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market 2